Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that its Principal Accounting Officer, Max A. Milbury, received a compensation-related grant of stock options. The award covers 18,167 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036. These options were granted at no cost and increase his directly held option position to 18,167 derivative securities. According to the disclosure, the options will vest ratably over four years, conditioned on his continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Milbury Max A.

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	18,167	$0.00	--

Holdings After Transaction: Option (right to buy) — 18,167 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 18,167 options Exercise price: $10.77 per share Expiration date: May 20, 2036 +2 more

5 metrics

Options granted 18,167 options Grant to Principal Accounting Officer on May 20, 2026

Exercise price $10.77 per share Exercise price for granted options

Expiration date May 20, 2036 Option term end date

Total options after grant 18,167 options Total derivative securities held following transaction

Vesting period Four years Options vest ratably over four years

Key Terms

Grant, award, or other acquisition, Principal Accounting Officer, Option (right to buy), vest ratably over four years

4 terms

Grant, award, or other acquisition financial

"transaction code description is "Grant, award, or other acquisition" for the options"

Principal Accounting Officer financial

"Max A. Milbury is identified as the Principal Accounting Officer of the issuer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

Option (right to buy) financial

"security title is listed as "Option (right to buy)" linked to Common Shares"

vest ratably over four years financial

"footnote states the shares subject to this option vest ratably over four years"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milbury Max A.

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		18,167		(1)	05/20/2036	Common Shares	18,167	$0	18,167	D

Explanation of Responses:

1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

	/s/ Max A. Milbury	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for Max A. Milbury?

ProMIS Neurosciences reported a grant of 18,167 stock options to Principal Accounting Officer Max A. Milbury. These options are a compensation-related award, not an open-market purchase or sale of Common Shares.

What is the exercise price of Max A. Milbury’s options at ProMIS Neurosciences (PMN)?

The granted options have an exercise price of $10.77 per Common Share. This means Milbury can buy up to 18,167 shares at $10.77 each once the options vest and are exercised.

When do Max A. Milbury’s ProMIS Neurosciences (PMN) options expire?

The options granted to Max A. Milbury expire on May 20, 2036. After this date, any unexercised options will lapse and can no longer be used to purchase Common Shares from the company.

How many ProMIS Neurosciences (PMN) options does Max A. Milbury hold after this grant?

Following this grant, Max A. Milbury holds 18,167 derivative securities in the form of stock options. This figure reflects his total directly held options position reported in the filing after the transaction.

How do Max A. Milbury’s ProMIS Neurosciences (PMN) options vest?

The filing states that the 18,167 options vest ratably over four years, subject to his continued service. This means portions of the award become exercisable over time as he remains with ProMIS Neurosciences.